Abstract 400P
Background
Breast cancer is the leading killer of female cancer patient. Lung cancer became the second affecting cancer (12%) but the main killer (25%) in female cancer patient. (Cancer fact and Figures 2017” report published by American Cancer Society) and odd of getting lung cancer are 1 in 17. In Bangladesh, the status and features of female lung cancer is not clear. In western country, female are more prone to lung cancer due to some risk factor like smoking, alcohol, exposure of radon etc than Bangladesh. We tried to find out the socio-demographic status and clinical features of lung cancer of female in Bangladesh.
Methods
This was a descriptive comparative observational study on 2396 female cancer patients reached at Outpatient of Medical oncology department of National Institute of cancer Research and Hospital, Mohakhali, Bangladesh from January 2018 to December 2018. Patients were selected purposive sampling method.
Results
Total number of 2396 female patients were included in this study. The average age of female lung cancer patient was 56.12 years and average weight was 45.32kg. We had found 336 lung cancer patients (14%) among the 2396 female cancer patient. 58% were adenocarcinoma, 26% were Squamous Cell, 7% small cell variety with undifferentiated and others like Sarcoma, mesothelioma etc were 9%. Most of the patients were illiterate (59%) and 79% patient were poor or below average economically. 42% female patient didn’t have any habitual problem. 46.82%% patients had the battle nut/ Jarda, 7.65% were smoker, about 10% had more than one habitual issue. At the time of presentation none of the had ECOG 0, patients had performance status O, most of the patient’s performance status (ECOG) were 1 (58%) ECOG2 were 27%. 39% patient had comorbidity, among them most frequent comorbidity was Hypertension which was 39% and second was DM (33%) and 20% patient having more than one comorbidity.
Conclusions
The percentage of female lung cancer in Bangladesh is pretty high among female cancer patient. female are most vulnerable group in rural area as well as they need special attention. Moreover, female lung cancer with other comorbidities makes the treatment more complicated for the cancer physician as well as brings the worst outcome. So, female lung cancer management should be personalized and comprehensive.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
412P - The evaluation of chromosomal changes in patients with osteosarcoma
Presenter: Nargiza Karimova
Session: Poster display session
Resources:
Abstract
413P - The state of molecular biological markers in osteosarcoma
Presenter: Djamilya Polatova
Session: Poster display session
Resources:
Abstract
414P - Clinical profile of gastrointestinal stromal tumour in Yangon General Hospital
Presenter: Khin Mu
Session: Poster display session
Resources:
Abstract
415P - Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy
Presenter: Florence Chamberlain
Session: Poster display session
Resources:
Abstract
417P - Clinicopathological profile and survival outcomes of sarcomas from a regional cancer centre in South India
Presenter: Divya Bharathi
Session: Poster display session
Resources:
Abstract
418P - Lessons learnt from treatment of foot sarcomas: Analysis from dedicated sarcoma clinic in North India
Presenter: Satyajit Pawar
Session: Poster display session
Resources:
Abstract
423P - Effectiveness of first-generation 5HT3 receptor antagonist plus dexamethasone plus aprepitant in controlling delayed chemotherapy-induced nausea and vomiting in patients with colorectal cancer: A propensity score-matched analysis
Presenter: Toshinobu Hayashi
Session: Poster display session
Resources:
Abstract
424P - Cancer worry, genetic knowledge, and attitudes towards NGS multigene panel testing among Korean breast cancer patients
Presenter: Ji Soo Park
Session: Poster display session
Resources:
Abstract
425P - Economic and safety evaluation of 5-HT3 recepter antagonist conversion from palonosetron to granisetron in highly and moderately emetogenic chemotherapy: A prospective study
Presenter: Keisuke Yamakita
Session: Poster display session
Resources:
Abstract
426P - Impaired quality of life of caregivers of patients with gastrointestinal cancer undergoing palliative chemotherapy
Presenter: Nobumichi Takeuchi
Session: Poster display session
Resources:
Abstract